Jazz Pharmaceuticals PLC (JAZZ)vsBeiGene, Ltd. (ONC)
JAZZ
Jazz Pharmaceuticals PLC
$189.08
+2.20%
HEALTHCARE · Cap: $11.39B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 25% more annual revenue ($5.34B vs $4.27B). ONC leads profitability with a 5.4% profit margin vs -8.3%. JAZZ earns a higher WallStSmart Score of 55/100 (C).
JAZZ
Buy55
out of 100
Grade: C
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JAZZ.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 24.6%
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
3.2% earnings growth
Weak financial health signals
ROE of -8.5% — below average capital efficiency
Distress zone — elevated risk
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : JAZZ
The strongest argument for JAZZ centers on PEG Ratio, Price/Book, Operating Margin. Revenue growth of 10.1% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
JAZZ profiles as a turnaround stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
JAZZ generates stronger free cash flow (297M), providing more financial flexibility.
Bottom Line
JAZZ scores higher overall (55/100 vs 42/100) and 10.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?